NYSE:UNH

UnitedHealth Group Inc (UNH)

428.79
+11.15 (2.67%)
as of Jul 28, 2026, 8:00:00 pm Market Open.
288 watching
0
Investor Insights
star iconJul 26, 2026, 12:00 am

This summary was created by AI, based on 41 opinions in the last 12 months.

UnitedHealth Group Inc (UNH) has faced significant challenges in the past year, including leadership changes, regulatory scrutiny, and headwinds from rising medical costs. Despite these issues, some analysts are optimistic about the long-term prospects, citing the company's strong position in the healthcare industry and the potential for recovery as costs are managed more effectively. There is a consensus that the return of a previous CEO could lead to better operational control, yet concerns about the future remain, particularly related to earnings projections and potential regulatory changes. While there are opinions on both sides regarding its current valuation, the stock has been seen as either undervalued or merely a defensive play amid turbulent market conditions.

consensus icon
Consensus
Mixed
valuation icon
Valuation
Fair Value
review icon
Similar
Cvs, CVS
BUY

It reports Thursday. Not too high of a PE and not overly loved and purely domestic. It has pricing power.

BUY ON WEAKNESS

Is up 10% in the past month. Don't chase a red hot stock, but let it come in a bit (lower). Every time this spikes, it goes down. It's best of breed.

BUY

Near term, this can't trade at prior multiples given volatility. Anything healthcare is uncertain. He still believes in the $600 price target. Great management. They have growth.

HOLD

Leader in the space. Trades at 16x forward PE, 11% growth. Last 5 years, earnings have growth 12% a year. 200-day MA trending higher, but price is a bit below that, so technical signals are neutral. Integrated model strong. Pricing power. Down 24% from recent highs on regulatory concerns, overdone.

BUY ON WEAKNESS

Is down 20% in 6 months and trades at 6.5x EBITA vs. 12x historically, strong managers, $20 billion free cash flow and new share buybacks.

PARTIAL SELL

The DOJ is going after them for Medicare payments. Is taking some risk off the table.

BUY ON WEAKNESS
Enter now on weakness?

Yes. It was a top pick of his last spring. He doesn't think there will be much negative impact from Washington investigating their billing practices, though there remains headline risk. Fundamentals are improving, though they are paying out more for medical costs, which he hopes will normalize. It's trading below the market PE, when usually it trades above.

TOP PICK

It is integral to the systematic delivery of health care across the U.S. and is a leader in well vertically integrated companies. There are some headwinds which he thinks will dissipate. He likes the longer term prospects and is seeing the development of per capita growth.
Buy 29  Hold 1  Sell 0

(Analysts’ price target is $633.30)
BUY
Value trap or buying opportunity?

He bought some yesterday. Didn't change guidance. Q4 profitability was OK, though revenue was a bit light. Health insurance in US will continue to grow, it's a leader. Core holding for him. Great distribution system, so cost is less than peers. Trump administration will not nationalize healthcare.

PAST TOP PICK
(A Top Pick Mar 17/23, Up 18%)

Well run and uses AI a lot. It's an easy punching bag in the US for critics of the healthcare system. Health is always a political hot knife, but HC is the biggest employer in the US. Some disagree, but it's not in their interest to screw customers (by denying claims). He has been this all the way down.

BUY

Healthcare stocks are no longer struggling with the post-Covid hangover, better earnings recently, and good news about Medicare this evening $21 billion payment boost). He expects a good report.

TOP PICK

Low beta, more conservative name. Very significant scale. Far ahead of peers with strong alignment of medical insurance, pharmacy benefits, and healthcare services. Aging demographics are key drivers of demand. Shares are 19% off their highs, an opportunity. 18x PE for 11% growth. Yield is 1.7%.

(Analysts’ price target is $641.46)
TOP PICK

Most diversified managed health care company (own clinics, software & insurance). Recent assassination of CEO not a major concern in terms of outlook for the business (although was a tragedy). Ability to raise prices very strong, with excellent margins on products. Will continue to buy shares. 

HOLD

The entire US health insurance group is embroiled in a controversy that was unfortunately set off by the murder of UNH, specifically talk about how claims are treated at UNH. These stocks are falling, but hang on and let this pass and see how different parties react. There will always be a place for health insurance companies in the US.

premiumPremium content

🔒 Premium Content Alert – This buzzing stock opinion is accessible only to Stockchase Premium

Discover an exclusive list and analysis of the stocks that are trending on social medias—accessible only to our Premium subscribers. With a keen focus on the stocks that are setting social media ablaze, this weekly feature offers an invaluable lens through which to evaluate market movers. Say goodbye to the endless scroll through social media timelines; we curate the buzz so you can invest your time as wisely as your money. Unlock Premium Now.

TOP PICK

Our mission is to help people live healthier lives and make the health system work better for everyone. We dedicate ourselves to this every day for our members by being there for what matters in moments big and small — from their earliest days to their working years and through retirement. Social media mentions are up 400% in the past 24h.

Showing 61 to 75 of 289 entries